Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans

Clinical Cancer Research

Volumn 9, Issue 7, 2003, Pages 2510-2519

  Iversen, Patrick L ^a   Arora, Vikram ^a   Acker, A J ^a   Mason, David H ^a   Devi, Gayathri R ^a  

^a AVI BIOPHARMA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AVI 144; AVI 4126; COMPLEMENTARY DNA; OLIGOMER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BACKACHE; BIOAVAILABILITY; CANCER INHIBITION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EXPERIMENTAL MODEL; FEMALE; GENE EXPRESSION; GENE TARGETING; HEADACHE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; INDIGESTION; INHIBITION KINETICS; LEG CRAMP; MALE; MOUSE; NECK PAIN; NONHUMAN; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; NUDE MOUSE; ONCOGENE C MYC; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; THORAX PAIN; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOWN-REGULATION; GENES, MYC; HUMANS; MALE; MICE; MICE, NUDE; MICROSCOPY, PHASE-CONTRAST; MORPHOLINES; NECROSIS; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDES, ANTISENSE; PROSTATIC NEOPLASMS; PROTEIN BIOSYNTHESIS; TIME FACTORS;

EID: 0037479844     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Landis, S. H., Murray, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1998. CA Cancer J. Clin., 48: 6-29, 1999.
2. Elo, J. P., and Visakorpi, T. Molecular genetics of prostate cancer. Ann. Med., 33: 130-141, 2001.
3. Amati, B., Alevizopoulos, K., and Vlach, J. Myc and the cell cycle. Front. Biosci., 3: 250-268, 1998.
4. Matusik, R. J. Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia. Cancer Res., 46: 1535-1538, 1986.
5. Lim, K., Park, C., Kim, Y. K., Yun, K. A., Son, M. Y., Lee, Y. C., Park, J. I., Lee, J. H., Sul, K., Lee, C. S., Park, S. K., and Hwang, B. D. Association of castration-dependent early induction of c-myc expression with a cell proliferation of the ventral prostate gland in rat. Exp. Mol. Med., 32: 216-221, 2000.
6. Nupponen, N. N., and Visakorpi, T. Molecular cytogenetics of prostate cancer. Microsc. Res. Tech., 51: 456-463, 2000.
7. Qian, J., Hirasawa, K., Bostwick, D. G., Bergstralh, E. J., Slezak, J. M., Anderl, K. L., Borell, T. J., Lieber, M. M., and Jenkins, R. B. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression. Mod. Pathol., 15: 35-44, 2002.
8. Kaltz-Wittmer, C., Klenk, U., Glaessgen, A., Aust, D. E., Diebold, J., Lohrs, U., and Baretton, G. B. FISH analysis of gene aberrations in advanced prostatic carcinomas before and after androgen deprivation therapy. Lab. Investig., 80: 1455-1464, 2000.
9. Helene, C., and Toulme, J. J. Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochim. Biophys. Acta. 1049: 99-125, 1990.
10. Summerton, J., and Weller, D. Morpholino antisense oligomers: design, preparation and properties. Antisense Nucleic Acid Drug Dev., 7: 187-195, 1997.
11. Summerton, J., Stein, D., Huang, S. B., Matthews, P., Weller, D., and Partridge, M. Morpholino and phosphorothioate oligomers compared in cell-free and in-cell systems. Antisense Nucleic Acid Drug Dev., 7: 63-70, 1997.
12. Giles, R. V., Spiller, D. G., Clark, R. E., and Tidd, D. M. Antisense morpholino oligonucleotide analog induces missplicing of c-myc mRNA. Antisense Nucleic Acid Drug Dev., 9: 213-220, 1999.
13. Ghosh, C., Stein, D., Weller, D., and Iversen, P. L. Evaluation of antisense mechanisms of action. Methds Enzymol., 313: 135-143, 2000.
14. Hudziak, R. M., Barofsky, E., Barofsky, D. F., Weller, D. L., Huang, S. B., and Weller, D. D. Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense Nucleic Acid Drug Dev., 6: 267-272, 1996.
15. Morcos, P. A. Achieving efficient delivery of morpholino oligos in cultured cells. Genesis, 30: 94-102, 2001.
16. Arora, V., Knapp, D. C., Smith, B. L., Statdfield, M. L., Stein, D. A., Reddy, M. T., Weller, D. D., and Iversen, P. L. C-Myc antisense limits rat liver regeneration and indicates role for c-myc in regulating cytochrome P-450 3A activity. J. Pharmacol. Exp. Ther., 292: 921-928, 2000.
17. Arora, V., Knapp, D. C., Reddy, M. T., Weller, D. D., and Iversen, P. L. Bioavailability and efficacy of antisense morpholino oligomers targeted to c-Myc and cytochrome P-450 3A2 following oral administration in rats. J. Pharm. Sci., 91: 1009-1017, 2002.
18. Smith, J. P., Verderame, M. F., and Zagon, I. S. Antisense oligonucleotides to gastrin inhibit growth of human pancreatic cancer. Cancer Lett., 135: 107-112, 1999.
19. Kanwar, J. R., Shen, W. P., Kanwar, R. K., Berg, R. W., and Krissansen, G. W. Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J. Natl. Cancer Inst. (Bethesda), 93: 1541-1552, 2001.
20. Sauter, E. R., Takemoto, R., Litwin, S., and Herlyn, M. p53 alone or in combination with antisense cyclin D1 induces apoptosis and reduces tumor size in human melanoma. Cancer Gene Ther., 9: 807-812, 2002.
21. Putzi, M. J., and De Marzo, A. M. Prostate pathology: histologic and molecular perspectives. Hematol. Oncol. Clin. N. Am., 15: 407-421, 2001.
22. Knox, J. J., and Moore, M. J. Treatment of hormone refractory prostate cancer. Semin. Urol. Oncol., 19: 202-211, 2001.
23. Gittes, R. F. Carcinoma of the prostate. N. Engl. J. Med., 324: 236-245, 1991.
24. Grad, J. M., Dai, J. L., Wu, S., and Burnstein, K. L. Multiple androgen response elements and a myc consensus site in the androgen receptor (AR) coding region are involved in androgen-mediated upregulation of AR messenger RNA. Mol. Endocrinol., 13: 1896-1911, 1999.
25. Zhang, X., Lee, C., Ng, P., Rubin, M., Shabsigh, A., and Buttyan, R. Prostatic neoplasia in transgenic mice with prostate-directed overexpression of the c-myc oncoprotein. Prostate, 43: 278-285, 2000.
26. Ganju, V., and Kvols, L. K. Molecular genetics of neuroendocrine tumors. Curr. Opin. Oncol., 5: 85-90, 1993.
27. van Waardenburg, R. C., Meijer, C., Pinto-Sietsma, S. J., de Vries, E. G., Timens, W., and Mulder, N. M. Effects of c-myc oncogene modulation on differentiation of human small cell lung carcinoma cell lines. Anticancer Res., 18: 91-95, 1998.
28. Bazarov, A. V., Adachi, S., Li, S. F., Mateyak, M. K., Wei, S., and Sedivy, J. M. A modest reduction in c-myc expression has minimal effects on cell growth and apoptosis but dramatically reduces susceptibility to Ras and Raf transformation. Cancer Res., 61: 1178-1186, 2001.
29. Balaji, K. C., Koul, H., Mitra, S., Maramag, C., Reddy, P., Menon, M., Malhotra, R. K., and Laxmanan, S. Antiproliferative effects of c-myc antisense oligonucleotide in prostate cancer cells: a novel therapy in prostate cancer. Urology, 6: 1007-1015, 1997.
30. Burgess, T. L., Fisher, E. F., Ross, S. L., Bready, J. V., Qian, Y. X., Bayewitch, L. A., Cohen, A. M., Herrera, C. J., Hu, S. S., and Kramer, T. B. The antiproliferative activity of c-myb and c-myc antisense oligomers in smooth muscle cells is caused by non-antisense mechanism. Proc. Natl. Acad. Sci. USA, 92: 4051-4055, 1995.
31. Iversen, P. L. PMO: favorable properties for sequence-specific inactivation. Curr. Opin. Mol. Ther., 3: 235-238, 2001.
32. Levin, A. A. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim. Biophys. Acta, 1489: 69-84, 1999.
33. Hudziak, R. M., Summerton, J., Weller, D. D., and Iversen, P. L. Antiproliferative effects of steric blocking phosphorodiamidate morpholino antisense agents directed against c-myc. Antisense Nucleic Acid Drug Dev., 10: 163-176, 2000.
34. Knapp, D. C., Mata, J. E., Reddy, M. T., Devi, G. R., and Iversen, P. L. Resistance to chemotherapeutic drugs overcome by c-Myc inhibition in Lewis lung carcinoma murine model. Anti-Cancer Drugs, 14: 39-47, 2003.
35. Devi, G. R., Oldenkamp, J. R., London, C. A., and Iversen, P. L. Inhibition of human chorionic gonadotropin β subunit modulates the mitogenic effect of c-myc in human prostate cancer cells. Prostate, 53: 200-210, 2002.
36. Ricker, J. L., Mata, J. E., Iversen, P. L., and Gattone, V. H. c-myc antisense oligomer treatment ameliorates murine infantile polycystic kidney disease. Kidney Int., 61: S125-S131, 2002.
37. Kipshidze, N., Keane, E., Stein, D., Chawla, P., Skrinska, V., Shankar, L. R., Khanna, A., Komorowski, R., Haudenschild, C., Iversen, P. L., Leon, M. B., Keelan, M. H., and Moses, J. Local delivery of c-myc neutrally charged antisense oligonucleotides with transport catheter inhibits myointimal hyperplasia and positively affects vascular remodeling in the rabbit balloon injury model. Catheter Cardiovasc. Interv., 54: 247-256, 2001.
38. Henry, S. P., Novotny, W., Leeds. J., Auletta, C., and Kornbrust, D. J. Inhibition of coagulation by a phosphorothioate oligonucleotide. Antisense Nucleic Acid Drug Dev., 7: 503-510, 1997.
39. Iversen, P. L., Cornish, K. G., Iversen, L. J., Mata, J. E., and Bylund, D. B. Bolus intravenous injection of phosphorothioate oligonucleotides causes hypotension by acting as α1-adrenergic receptor antagonists. Toxicol. Appl. Pharmacol., 160: 289-296, 1999.
40. Tang, D. G., and Porter, A. T. Target to apoptosis: a hopeful weapon for prostate cancer. Prostate, 32: 284-293, 1997.
41. Devi, G. R. Prostate cancer: status of current treatments and emerging antisense-based therapies. Curr. Opin. Mol. Ther., 4: 138-148, 2002.
42. Pawlak, W., Zolnierek, J., Sarosiek, T., and Szczylik, C. Antisense therapy in cancer. Cancer Treat. Rev., 26: 333-350, 2000.